{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.1444.5.226","meta":{"versionId":"12","lastUpdated":"2022-03-02T18:03:26.000-05:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.226","version":"20210320","name":"Immunotherapy Administration","status":"active","date":"2022-03-03T18:46:01-05:00","publisher":"American Society of Clinical Oncology Steward","compose":{"include":[{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.177"]},{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.175"]},{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.174"]}]},"expansion":{"identifier":"urn:uuid:70d6711d-94d7-4833-91ef-4fd7ce71dfc3","timestamp":"2022-06-10T08:41:16-04:00","total":22,"offset":0,"parameter":[{"name":"count","valueInteger":1000},{"name":"offset","valueInteger":0}],"contains":[{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"0540T","display":"Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20220301","code":"180223008","display":"Intravenous immunotherapy (procedure)"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20220301","code":"180244008","display":"Intramuscular immunotherapy (procedure)"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20220301","code":"180256009","display":"Subcutaneous immunotherapy (procedure)"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20220301","code":"589631000119102","display":"Intravenous radioimmunotherapy using monoclonal antibodies (procedure)"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20220301","code":"60827006","display":"Lymphokine activated killer cell therapy (procedure)"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20220301","code":"64644003","display":"Immunotherapy for cancer (procedure)"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20220301","code":"72255009","display":"Interleukin-2 therapy (procedure)"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20220301","code":"76334006","display":"Immunotherapy (procedure)"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20220301","code":"84501003","display":"Cytokine therapy (procedure)"},{"system":"http://snomed.info/sct","version":"http://snomed.info/sct/731000124108/version/20220301","code":"870387009","display":"Immune checkpoint inhibitor therapy (procedure)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"96365","display":"Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"96366","display":"Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"96372","display":"Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"96374","display":"Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"96401","display":"Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"96409","display":"Chemotherapy administration; intravenous, push technique, single or initial substance/drug"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"96413","display":"Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"96415","display":"Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"96416","display":"Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2022","code":"Q2041","display":"Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2022","code":"Q2042","display":"Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose"}]}}